Several disturbances in thought processes occur in persons with MS, including slowed cognition, impaired concentration and memory, loss of complex language, and impaired problem solving and decision-making capacity. There is no simple tool available to assess subtle cognitive losses in primary care settings.
|
|
Robert J. Fox, MD (Program Chair)
Nilay Shah, MD
Jeffrey A. Wilken, PhD |
The clinician treating a patient who has moved from relapsing-remitting MS to the progressing form of the disease faces difficult management decisions. This case-based program will explore expert opinions on available treatment options and follow up care in this challenging situation.
|
|
Robert J. Fox, MD (Program Chair)
Nilay Shah, MD
|
This case-based presentation will look at the clinical challenges of a patient who presents in disease remission but who has a progressively worsening picture on MRI.
|
|
Robert J. Fox, MD (Program Chair)
Nilay Shah, MD
(Program Chair)
J. Theodore Phillips, MD, PhD |
The benefits of interferon-beta therapy have been shown to be greater in clinically isolated syndromes and relapsing-remitting MS than in secondary progressive MS.
|
|
Robert J. Fox, MD (Program Chair)
Nilay Shah, MD
(Program Chair)
Randall T. Schapiro, MD |
|
|
 |
|
 |
|
|
|
 |
How do you manage patients that report paralyzing symptoms in one or both legs post injection of interferon (beta-1a)? Should these patients continue therapy or are there any medications that can be given to prevent or manage this reaction? |
|
|
|
|
 |
Two different post-interferon injection syndromes seem to account for most of these events: First, even relatively small increases in core body temperature post-injection can result in temporary, but reversible leg muscle weakness. The pathophysiology of this seems to be closely related to the well-known Uhthoff's phenomenon.
|
|
|
|
|
|
|
|
|
|
